Literature DB >> 7887012

Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus.

B Brochier1, D Boulanger, F Costy, P P Pastoret.   

Abstract

Oral immunization of foxes by distributing vaccine baits was experimentally assessed and subsequently employed in the whole of the infected area of Belgium (10,000 km2). A vaccinia-rabies glycoprotein recombinant virus (VR-G) was used as vaccine because of its efficacy, safety and heat stability. Five 'full' campaigns of fox vaccination, carried out from 1989 until 1991, induced a drastic decrease in the incidence of rabies. The disease has disappeared from the major part of the initial infected area. In 1992 and 1993, three 'defence' campaigns, carried out along international borders, completely eliminated rabies virus infection from the fox population in 1993.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7887012     DOI: 10.1016/0264-410x(94)90143-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Harvesting blood proteins from grain.

Authors:  A Robinson
Journal:  CMAJ       Date:  1995-08-15       Impact factor: 8.262

2.  Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.

Authors:  Rajesh Thippeshappa; Baoping Tian; Brad Cleveland; Wenjin Guo; Patricia Polacino; Shiu-Lok Hu
Journal:  Clin Vaccine Immunol       Date:  2015-12-30

3.  The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur.

Authors:  P P Pastoret; B Brochier
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

4.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.